Navigation Links
Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients
Date:10/22/2008

V3100

Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than 1 million men in the United States have prostate cancer. An estimated 186,320 new cases are expected to be diagnosed in 2008, and approximately 28,660 men are expected to die this year from the disease. Patients with castration-resistant (also known as hormone-refractory) prostate cancer have few treatment options and a poor prognosis.

Overexpression of the androgen receptor is believed to contribute to the progression of castration-resistant prostate cancer. MDV3100 is a novel small- molecule androgen receptor antagonist that inhibits androgen receptor function by blocking nuclear translocation of the androgen receptor and DNA binding.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. The Company's current clinical development program includes a pivotal and confirmatory Phase 3 trial of Dimebon in Alzheimer's disease and a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer. Medivation recently announced that it plans to continue further development of Dimebon in patients with mild-to-moderate Huntington's disease based on the positive results seen in its Phase 2 trial. In September 2008, Medivation entered into a global agreement with Pfizer Inc to develop and commercialize Dimebon for the treatment of Alzheimer's and Huntington's diseases. For more information, please visit us at http://www.medivation.com.

This press release contains forward-looking statements, including statements regarding future clini
'/>"/>

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Medivation Receives Corporate Achievement Award From Huntingtons Disease Society of America
2. Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Partnering Plans for Dimebon
3. Medivation Announces Participation in Upcoming Conferences
4. Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update
5. Medivation Announces Second Quarter 2008 Teleconference and Webcast on August 11, 2008
6. Medivation Announces Presentation at the BMO Capital Markets 2008 Focus on Healthcare Conference on August 5
7. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients
8. Medivation Announces Senior Management Promotions
9. Medivation Reports Year-End 2007 Financial Results and Pipeline Progress
10. Medivation Announces Participation in Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
11. Medivation Selected as Founding Member of New NASDAQ(R) NeuroInsights(R) Neurotech Index
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Francisco, CA (PRWEB) May 23, 2013 ... who encourage all types of inventions. They focus on ... now noticing this community gravitate toward bringing their ideas ... the DIY Biology Movement, works on making projects using ... the DNA of plants to make them glow with ...
(Date:5/23/2013)... May 23, 2013 VG Energy, an ... with DAK Renewable Research to conduct field trials ... VG Energy is a majority owned subsidiary of ... VG Energy,s exclusively licensed compound LipidMax selectively ... yield in plants, possessing a wide variety of ...
(Date:5/23/2013)... 2013 Virobay, Inc. today announced that their ... an important milestone, as Virobay has now initiated a ... cathepsin S inhibitor.   The first Phase ... study designed to evaluate the safety, tolerability, pharmacokinetics and ... "The initiation of this Phase 1 trial ...
(Date:5/23/2013)... 23, 2013 On April 19th the ... supermarkets to search for the growing antibiotic resistant bacteria ... from a year long study were released late last ... specifically meats, over previous years. For those suffering from ... of antibiotic resistant bacteria in food, may eventually help ...
Breaking Biology Technology:Glowing Plant Releases Maker Kit, Enabling Anyone to Make a Glowing Plant at Home 2VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 2VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 3Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3Acne Cream, Probiotic Action Shares News on How Some Food may Breed Acne Causing Bacteria 2
...   Reprints Desk, Inc., a Derycz Scientific (OTC.BB:DYSC) company, ... features in Bibliogo, the journal article web app that ... to individual users who sign up at www.bibliogo.com ... save time accessing full-text papers from PubMed and ...
... Feb. 2, 2012 Auxogyn, Inc., a privately-held company focused ... the final tranche of its Series A financing, bringing the ... in May 2010, and investors in the round include Kleiner ... "Over the course of the last year, we ...
... Cambrex Corporation (NYSE: CBM ) announced that ... Monday, February 6, 2012 after the market closes. ... to discuss the fourth quarter 2011 financial results.  , ... February 7, 2012 at 8:30 a.m. Eastern Time  Dial-in:1-866-719-0110 ...
Cached Biology Technology:PubMed Users Now Save Time Accessing and Organizing Scientific Papers by Using Bibliogo From Reprints Desk 2PubMed Users Now Save Time Accessing and Organizing Scientific Papers by Using Bibliogo From Reprints Desk 3Auxogyn Completes $20 Million In Series A Funding 2Auxogyn Completes $20 Million In Series A Funding 3
(Date:5/22/2013)... The feared Legionella pneumophila bacteria is responsible ... pneumonia. In order to infect us, this pathogen has ... and go unnoticed in our cells, thus avoiding these ... the Basque biosciences research centre, CIC bioGUNE, in which ... the USA and the National Supercomputation Centre in Barcelona ...
(Date:5/22/2013)... of pollinating insects and wild plants have slowed in ... led by the University of Leeds and the Naturalis ... dramatic reductions in the diversity of species in Britain, ... , But the picture brightened markedly after 1990, with ... bees, hoverflies and wild plants. , Professor ...
(Date:5/21/2013)... a whale entangled in fishing gear, scientists showed for ... diving and swimming behavior. The monitoring revealed how fishing ... their energy as they drag gear for months or ... The scientists in this entanglement response suction-cupped a cellphone-size ... Atlantic right whale called Eg 3911. The Dtag, developed ...
Breaking Biology News(10 mins):Mechanism discovered which aids Legionella to camouflage itself in the organism 2Encouraging signs for bee biodiversity 2Encouraging signs for bee biodiversity 3Study reveals how fishing gear can cause slow death of whales 2Study reveals how fishing gear can cause slow death of whales 3
... surviving, growing and reproducing out of control. And signals ... growing or to die. In breast cancer, one tricky ... and sometimes suppressing them. A University of Colorado ... Oncogene details how tumors may flip the TGF-beta ...
... Texas at Austin researchers have demonstrated a new and ... heart and limbs a research advancement that could ... the leading cause of death in the Western world. ... Engineering Assistant Professor Aaron Baker could allow doctors to ...
... This press release is available in German . ... has approved the establishment of four new Research Units. This ... meeting in Bonn. The purpose of the research consortia is ... topical questions in their disciplines and to establish innovative research ...
Cached Biology News:Study details on-off switch that promotes or suppresses breast cancer 2New ability to regrow blood vessels holds promise for treatment of heart disease 2New ability to regrow blood vessels holds promise for treatment of heart disease 3DFG to establish 4 new research units 2DFG to establish 4 new research units 3
ANTI CORTIS BIN GLOB...
MOUSE ANTI BOVINE WC1:FITC Immunogen: Bovine lymphocytes...
ANTI S. ENTERID LPS...
... contains the basic components required for the ... and recombinant Feline IL-10 in cell culture ... materials to run ELISAs on approximately fifteen ... are met: The assay is run ...
Biology Products: